Combination treatment for advanced lung cancer after immunotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of two drugs—an immunotherapy called tislelizumab and an experimental antibody-drug conjugate called SYS6010—for people with advanced non-small cell lung cancer who have already tried immunotherapy and their cancer continued to grow. The goal is to see if this combination can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer that cannot be cured with surgery or radiation.
- Your tumor does not have certain gene changes (EGFR, ALK, or ROS1).
- You have already been treated with an immunotherapy drug (PD-1 or PD-L1 inhibitor) and your cancer got worse despite that treatment.
- You must be able to undergo a tumor biopsy before and during the study, if needed.
- You are in good enough health to carry out daily activities (ECOG score 0 or 1), and you have at least 3 months to live.
- Your blood counts, kidney, liver, and clotting tests are within acceptable ranges, and any past treatment side effects have mostly resolved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
This trial tests a combination of tislelizumab (an immunotherapy drug) with chemotherapy for people with a type of lung cancer that has not spread to other organs and cannot be removed with surgery. The goal is to see if this treatment can shrink tumors and help people live longer.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This trial tests whether giving an experimental drug (SYS6010) together with an immunotherapy (a type of treatment that helps your immune system fight cancer) after surgery can lower the chance of cancer coming back. It's for people with non-small cell lung cancer that was completely removed but didn't respond very well to surgery alone.
This trial tests a new drug, SYS6090, combined with other treatments for advanced non-small cell or small cell lung cancer that has spread and can't be removed by surgery. It aims to see if this combination can help shrink or control the cancer, and how safe it is for patients.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.